153182-30-0

Basic information

• Product Name: (4R,5S,6S,7R)-4,7-dibenzyl-1,3-bis[(4-fluorophenyl)methyl]-5,6-dihydro xy-1,3-diazepan-2-one
• Synonyms: (4R,5S,6S,7R)-4,7-dibenzyl-1,3-bis[(4-fluorophenyl)methyl]-5,6-dihydro xy-1,3-diazepan-2-one
• CAS NO: 153182-30-0
• Molecular Formula: C33H32F2N2O3
• Molecular Weight: 542.62
• Mol File: 153182-30-0.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 704.5°Cat760mmHg
• Flash Point: 379.9°C
• Appearance: /
• Density: 1.296g/cm³
• Vapor Pressure: 7.85E-21mmHg at 25°C
• Refractive Index: 1.636
• CAS DataBase Reference: (4R,5S,6S,7R)-4,7-dibenzyl-1,3-bis[(4-fluorophenyl)methyl]-5,6-dihydro xy-1,3-diazepan-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (4R,5S,6S,7R)-4,7-dibenzyl-1,3-bis[(4-fluorophenyl)methyl]-5,6-dihydro xy-1,3-diazepan-2-one(153182-30-0)
• EPA Substance Registry System: (4R,5S,6S,7R)-4,7-dibenzyl-1,3-bis[(4-fluorophenyl)methyl]-5,6-dihydro xy-1,3-diazepan-2-one(153182-30-0)

Safety Data

• Hazardous Substances Data: 153182-30-0(Hazardous Substances Data)

Usage

Description

(4R,5S,6S,7R)-4,7-dibenzyl-1,3-bis[(4-fluorophenyl)methyl]-5,6-dihydroxy-1,3-diazepan-2-one is a complex chiral chemical compound belonging to the class of diazepan-2-ones. It features four asymmetric carbon centers, two benzyl groups, two fluorophenylmethyl groups, a dihydroxy group, and a diazepan ring structure. Its intricate molecular architecture suggests potential applications in various fields, including medicinal chemistry, drug development, and organic synthesis.

Uses

Used in Medicinal Chemistry:
(4R,5S,6S,7R)-4,7-dibenzyl-1,3-bis[(4-fluorophenyl)methyl]-5,6-dihydroxy-1,3-diazepan-2-one is used as a compound in medicinal chemistry for its potential to be developed into new drugs or therapeutic agents. Its unique structure may allow for specific interactions with biological targets, potentially leading to novel treatments for various diseases.
Used in Drug Development:
In the field of drug development, (4R,5S,6S,7R)-4,7-dibenzyl-1,3-bis[(4-fluorophenyl)methyl]-5,6-dihydroxy-1,3-diazepan-2-one is used as a starting material or a structural component for designing new pharmaceuticals. Its chirality and functional groups may offer advantages in creating targeted and effective medications.
Used in Organic Synthesis:
(4R,5S,6S,7R)-4,7-dibenzyl-1,3-bis[(4-fluorophenyl)methyl]-5,6-dihydroxy-1,3-diazepan-2-one is used as a synthetic intermediate or a building block in organic synthesis. Its versatile structure can be further modified or functionalized to create a range of new compounds with different properties and applications.

InChI:InChI=1/C33H32F2N2O3/c34-27-15-11-25(12-16-27)21-36-29(19-23-7-3-1-4-8-23)31(38)32(39)30(20-24-9-5-2-6-10-24)37(33(36)40)22-26-13-17-28(35)18-14-26/h1-18,29-32,38-39H,19-22H2/t29-,30-,31+,32+/m1/s1

Upstream product

• 1053696-57-3 (4R,5S,6S,7R)-4,7-Dibenzyl-1,3-bis-(4-fluoro-benzyl)-5,6-bis-(2-trimethylsilanyl-ethoxymethoxy)-[1,3]diazepan-2-one 
• 459-46-1 4-Fluorobenzyl bromide 
• 153181-22-7 (4R,5S,6S,7R)-hexahydro-5,6-bis[2-(trimethylsilyl)ethoxymethoxy]-4,7-bis(phenylmethyl)-2H-1,3-diazepin-2-one 
• 58917-85-4 N-(benzyloxycarbonyl)-D-phenylalaninol 
• 63219-70-5 N-(benzyloxycarbonyl)-D-phenylalaninal 
• 183814-19-9 ((1S,2R,3S,4R)-1-Benzyl-4-benzyloxycarbonylamino-2,3-dihydroxy-5-phenyl-pentyl)-carbamic acid benzyl ester 

Relevant articles and documents

Calculated and experimental low-energy conformations of cyclic urea HIV protease inhibitors

One important factor influencing the affinity of a flexible ligand for a receptor is the internal strain energy required to attain the bound conformation. Calculation of fully equilibrated ensembles of bound and free ligand and receptor conformations are computationally not possible for most systems of biological interest; therefore, the qualitative evaluation of a novel structure as a potential high- affinity ligand for a given receptor can benefit from taking into account both the bound and unbound (usually aqueous) low-energy geometries of the ligand and the difference in their internal energies. Although many techniques for computationally generating and evaluating the conformational preferences of small molecules are available, there are a limited number of studies of complex organics that compare calculated and experimentally observed conformations. To assess our ability to predict a priori favored conformations of cyclic HIV protease (HIV-1 PR) inhibitors, conformational minima for nine 4,7- bis(phenylmethyl)-2H-1,3-diazepin-2-ones I (cyclic ureas) were calculated using a high temperature quenched dynamics (QD) protocol. Single crystal X-ray and aqueous NMR structures of free cyclic ureas were obtained, and the calculated low-energy conformations compared with the experimentally observed structures. In each case the ring conformation observed experimentally is also found in the lowest energy structure of the QD analysis, although significantly different ring conformations are observed at only slightly higher energy. The 4- and 7-benzyl groups retain similar orientations in calculated and experimental structures, but torsion angles of substituents on the urea nitrogens differ in several cases. The data on experimental and calculated cyclic urea conformations and their binding affinities to HIV-1 PR are proposed as a useful dataset for assessing affinity prediction methods.